|
|
Endocrinology
Research Funding
(listed alphabetically by Principal Investigator)
Pediatric Clinical Translational Research Center
Principal Investigator: Richard D. Krugman, MD
Program Director: Ronald J. Sokol, MD
Associate Program Director: William W. Hay, Jr., MD
Associate Program Director: Philip S. Zeitler, MD, PhD
Assistant Program Director: Nancy F. Krebs, MD
Source: National Institutes of Health, National Center for Research Resources - M01-RR00069
Amount: $16,884,197
Term: 2001-2006
Treatment Alternatives in Pediatric Type 2 Diabetes
Principal Investigator: Philip S. Zeitler, MD, PhD
Co-Investigators: Georgeanna J. Klingensmith, MD, and Nancy F. Krebs, MD
Source: National Institutes of Health - 5U01 DK61242
Amount: $508,000/yr
Term: 2002-2009
Defining Diabetes in Youth - Ethnic Diversity in Three Populations
Principal Investigator: Richard F. Hamman, MD, DrPH
Co-Investigator: Philip S. Zeitler, MD, PhD
Source: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases - 1R01DK059184-01A2
Amount: $500,000/yr
Term: 2002-2006
Career Development Award (K23)
Principal Investigator: Kristen Nadeau, MD
Source: National Institutes of Health, National Center for Research Resources - 1 K23 RR020038-01
Amount: $131,330/yr
Term: 2004-2006
2003-2004
Defining Diabetes in Youth - Ethnic Diversity in Three Populations
Principal Investigator: Philip S. Zeitler, MD, PhD
Source: National Institutes of Health - 1 U01 DK61242-01
Amount: $500,000/yr
Term: 2002-2005
The Physiology of Growth Hormone-Releasing Hormone (GHRH) in Breast Cancer
Principal Investigator: Philip S. Zeitler, MD, PhD
Source: US Department of Defense Breast Cancer Research Program - BC990426
Amount: $74,954/yr
Term: 2000-2003
The Prevalence and Natural History of Osteopenia and Osteoporosis in Survivors of Childhood Bone Marrow Transplant
Principal Investigator: Philip S. Zeitler, MD, PhD
Source: Pediatric General Clinical Research Center
Term: 2000-2005
Treatment Alternatives in Pediatric Type 2 Diabetes
Principal Investigator: Philip S. Zeitler, MD, PhD
Co-Investigators: Georgeanna J. Klingensmith, MD, and Nancy F. Krebs, MD
Source: National Institutes of Health - 1U01 DK61242-01
Amount: $433,670/yr
Term: 2001-2009
2001-2002
An Open-Label Trial Evaluating the Safety and Efficacy of NOLVADEX (TOMAXIFEN-CITRATE) in the Treatment of McCune Albright Syndrome
Principal Investigator: Michael S. Kappy, MD, PhD
Source: AstraZeneca Pharmaceuticals
Amount: $10,000 per patient enrolled
Term: 2000-2002
A Randomized, Double-Blind Placebo-Controlled Trial to Assess the Safety and Efficacy of (ARIMEDEX) vs. Placebo for the Treatment of Gynceocmastia of Pubertal Boys
Principal Investigator: Michael S. Kappy, MD, PhD
Source: AstraZeneca Pharmaceuticals
Amount: $6,200 per patient enrolled
Term: 2000-2002
A Double-Blind, Placebo-Controlled 52-Week Study of Xenical (Orlistat) in the Weight Management of Obese Pediatric Patients
Principal Investigator: Sharon H. Travers, MD
Source: F. Hoffmann-La Roche Ltd
Amount: $ 6,326 per patient enrolled
Term: 2000-2001
The Effect of Recombinant Human Growth Hormone Treatment on the Growth of Infants and Toddlers with Turner Syndrome
Principal Investigator: Sharon H. Travers, MD
Source: Eli Lilly Pharmaceuticals
Amount: $6,326 per patient enrolled
Term: 1999-2002
Defining Diabetes in Youth - Ethnic Diversity in Three Populations
Principal Investigator: Philip S. Zeitler, MD, PhD
Source: National Institutes of Health - 1 U01 DK61242-01
Amount: $500,000/yr
Term: 2002-2005
The Hypopituitary Control and Complications Study (HypoCCS-1)
Principal Investigator: Philip S. Zeitler, MD, PhD
Source: Eli Lilly Pharmaceuticals
Amount: $1,425 per patient enrolled
Term: 1999-2002
The Physiology of Growth Hormone-Releasing Hormone (GHRH) in Breast Cancer
Principal Investigator: Philip S. Zeitler, MD, PhD
Source: US Department of Defense Breast Cancer Research Program - BC990426
Amount: $74,954/yr
Term: 2000-2003
The Prevalence and Natural History of Osteopenia and Osteoporosis in Survivors of Childhood Bone Marrow Transplant
Principal Investigator: Philip S. Zeitler, MD, PhD
Source: Pediatric General Clinical Research Center
Term: 2000-2005
Treatment Alternatives in Pediatric Type 2 Diabetes
Principal Investigator: Philip S. Zeitler, MD, PhD
Co-Investigators: Georgeanna J. Klingensmith, MD, and Nancy F. Krebs, MD
Source: National Institutes of Health - 1U01 DK61242-01
Amount: $433,670/yr
Term: 2001-2008
The Use of Bisphosphonates to Treat Osteoporosis in Children with Steroid-Dependent Asthma
Principal Investigator: Philip S. Zeitler, MD, PhD
Source: The Children's Hospital Research Institute
Amount: $30,000
Term: 1999-2001
The Use of Pamidronate to Treat Osteoporosis in Children with Steroid-Dependent Asthma
Principal Investigator: Philip S. Zeitler, MD, PhD
Source: Novartis Pharmaceuticals Corporation
Amount: $20,000
Term: 2000-2001
1999-2000
An Open-Label Trial Evaluating the Safety and Efficacy of NOLVADEX (TOMAXIFEN-CITRATE) in the Treatment of McCune Albright Syndrome
Principal Investigator: Michael S. Kappy, MD, PhD
Source: AstraZeneca Pharmaceuticals
Amount: $10,000 per patient enrolled
Term: 2000-ongoing
A Randomized, Double-Blind Placebo-Controlled Trial to Assess the Safety and Efficacy of (ARIMEDEX) vs. Placebo for the Treatment of Gynceocmastia of Pubertal Boys
Principal Investigator: Michael S. Kappy, MD, PhD
Source: AstraZeneca Pharmaceuticals
Amount: $6,200 per patient enrolled
Term: 2000-ongoing
The Effect of Recombinant Human Growth Hormone Treatment on the Growth of Infants and Toddlers with Turner's Syndrome
Principal Investigator: Sharon H. Travers, MD
Source: Eli Lilly Pharmaceuticals
Amount: $6,326 per patient enrolled
Term: 1999-2001
A Double-Blind, Placebo-Controlled 52 Week Study of Xenical (orlistat) in the Weight Management of Obese Pediatric Patients
Principal Investigator: Sharon H. Travers, MD
Source: F. Hoffmann-La Roche
Amount: $ 6,326 per patient enrolled
Term: 2000-2001
The Use of Bisphosphonates to Treat Osteoporosis in Children with Steroid Dependent Asthma
Principal Investigator: Philip Zeitler, MD, PhD
Source: Children's Hospital Research Institute
Amount: $30,000
Term: 1999-2001
The Use of Pamidronate to Treat Osteoporosis in Children with Steroid Dependent Asthma
Principal Investigator: Philip Zeitler, MD, PhD
Source: Novartis Pharmaceuticals
Amount: $20,000
Term: 2000-2001
The Physiology of Growth Hormone-Releasing Hormone (GHRH) in Breast Cancer
Principal Investigator: Philip Zeitler, MD, PhD
Source: Department of Defense Breast Cancer Research Program
Amount: $74,954/yr
Term: 2000-2003
Growth Impairment and Adrenal Suppression in Children Receiving High-Dose Inhaled Steroid Therapy for Asthma
Principal Investigator: Philip Zeitler, MD, PhD
Source: Genentech Institute for Growth
Amount: $50,000
Term: 2000-2002
The Hypopituitary Control and Complications Study (HypoCCS)
Principal Investigator: Philip Zeitler, MD, PhD
Source: Eli Lilly Pharmaceuticals
Amount: $1,425 per patient enrolled
Term: 1999-ongoing
The Hypopituitary Control and Complications Study (HypoCCS-1)
Principal Investigator: Philip Zeitler, MD, PhD
Source: Eli Lilly Pharmaceuticals
Amount: $1,425 per patient enrolled
Term: 1999-ongoing
|
|
